Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arbutus Biopharma Corp ABUS

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran is its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic product candidate. AB-101 is an oral PD-L1 inhibitor that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for.


NDAQ:ABUS - Post by User

Bullboard Posts
Post by grover11on Oct 05, 2014 12:26pm
130 Views
Post# 22999980

Wouldn't want to be short

Wouldn't want to be short

Marburg breaks out in Uganda...Developing

Deadly Marburg hemorrhagic fever breaks out in Uganda 
he deadly Marburg hemorrhagic fever has broken out in Uganda after samples taken to the Uganda Virus Institute tested positive, a top government official said Sunday. 

Elioda Tumwesigye, minister of state for health told reporters that one person has so far died and 80 others are being monitored in central Uganda and the western district of Kasese. 

"The Ministry of Health would like to inform the country of an outbreak Marburg which has so far killed one person. Another person who has developed signs is being monitored," he said. 

He said the index case died on Sept. 28 after developing signs of Marburg which was later confirmed by laboratory tests. The minister said the deceased's brother has also developed signs and is currently under isolation. 

He added that all the people that had contact with them are being monitored. 

The Marburg virus was last reported in Uganda in 2012. 

According to the World Health Organization, Marburg is a severe and highly fatal disease caused by a virus from the same family as the one that causes Ebola hemorrhagic fever. 

According to the global health body, the illness caused by Marburg virus begins abruptly, with severe headache and malaise. 

Case fatality rates have varied greatly, from 25 percent in the initial laboratory-associated outbreak in 1967, to more than 80 percent in the Democratic Republic of Congo from 1998-2000, to even higher in the outbreak that began in Angola in late 2004. 

Currently some West African states are facing a related disease- - Ebola -- which has left more than 3,000 people dead
Bullboard Posts